AMFI Stock Reclassification Preview (Dec 2022): A Bunch of Migrations
Near the end of the review period, we see 7 stocks moving from MidCap to LargeCap, 6 from LargeCap to MidCap, 8 from SmallCap to MidCap and vice...
Gland Pharma LTD - Intense Competition & Moderate Demand Leads to Business Loss
Gross margin in RoW business declined to ~25% in Q2FY23 (vs. ~35% in Q2FY22) due to higher freight cost (included in COGS) as it airlifted critical...
NIFTY Indices: HDFC/HDFCB Merger Driven Market Consultation
NSE Indices' market consultation on merger/demerger treatment will significantly reduce index turnover. We expect the HDFC/HDFCB merger to complete...
Pharma Q2fy23 Preview
The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY. Currency (Rs) has depreciated by 5.0%
Smartkarma Originals